Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
Provided By GlobeNewswire
Last update: Feb 6, 2025
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management
Read more at globenewswire.comNASDAQ:DARE (4/24/2025, 4:30:01 PM)
3
-0.01 (-0.33%)
Find more stocks in the Stock Screener
